{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:13:34Z","timestamp":1789992814232,"version":"4.0.1"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T00:00:00Z","timestamp":1318809600000},"content-version":"vor","delay-in-days":46,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Peripheral Nervous Sys"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:p>Guillain\u2010Barr\u00e9 syndrome (GBS) is a (sub)acute polyradiculoneuropathy, which may occur following immunization. To interpret the occurrence of GBS after introduction of large\u2010scale immunization programmes, it is important to define recent background incidence rates (IRs) of GBS. We used a general practitioner electronic medical record database to assess age\u2010specific GBS IRs between 1996 and 2008 in The Netherlands. All possible GBS cases were manually reviewed. Validated incident cases were reviewed by a neurologist (B. J.) for diagnostic certainty using the GBS case definition of the Brighton Collaboration (BC). In a population of 638,891 persons, we identified 23 validated incident GBS cases (mean age 46 years). IR was 1.14 per 100,000 person years (95% confidence interval [CI] 0.67\u20131.61) and was lower for people under 50 years (0.76; 95%CI 0.41\u20131.32) compared with elderly of 50 years or older (1.80; 95%CI 0.98\u20133.05). Only six cases fulfilled level 1 or 2 of diagnostic certainty of the BC case definition. IR of GBS increases with age. As vaccinations are often targeted at specific age groups, age\u2010specific rates should be used to monitor GBS observed versus expected rates after introduction of large\u2010scale vaccination programmes.<\/jats:p>","DOI":"10.1111\/j.1529-8027.2011.00356.x","type":"journal-article","created":{"date-parts":[[2011,10,17]],"date-time":"2011-10-17T11:59:27Z","timestamp":1318852767000},"page":"243-249","source":"Crossref","is-referenced-by-count":16,"title":["Guillain\u2010Barr\u00e9 syndrome: background incidence rates in The Netherlands"],"prefix":"10.1111","volume":"16","author":[{"given":"Nicoline A. T.","family":"van der Maas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merlijn A.","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart C.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"van Soest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne P.","family":"Dieleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanet M.","family":"Kemmeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester E.","family":"de Melker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam C. J. M.","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,17]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410270707"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61877-8"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s100720200036"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00511-5"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.02.106"},{"key":"e_1_2_5_7_1","unstructured":"Centers for Disease Control and Prevention (CDC)(2005).Guillain\u2010Barr\u00e9 syndrome among recipients of Menactra\u00ae meningococcal conjugate vaccine \u2013 United States June\u2010July 2005.Mmwr Morb Mortal Wkly Rep 54:1023\u20131025."},{"key":"e_1_2_5_8_1","unstructured":"Centers for Disease Control and Prevention (CDC)(2010).Preliminary results: surveillance for Guillain\u2010Barr\u00e9 syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine \u2013 United States 2009\u20132010.Mmwr Morb Mortal Wkly Rep 59:657\u2013661."},{"key":"e_1_2_5_9_1","unstructured":"Gezondheidsraad(2007). Griepvaccinatie: herziening van de indicatiestelling. Den Haag: Gezondheidsraad; publicatienr.2007\/ 09.ISBN978\u201090\u20105549\u2010638\u20109."},{"key":"e_1_2_5_10_1","unstructured":"Gezondheidsraad(2008). Vaccinatie tegen baarmoederhalskanker. Den Haag: Gezondheidsraad; publicatienr.2008\/ 08.ISBN978\u201090\u20105549\u2010702\u20107."},{"key":"e_1_2_5_11_1","unstructured":"Gezondheidsraad(2009). Vaccinatie tegen pandemische influenza A\/H1N12009: doelgroepen en prioritering. Den Haag: Gezondheidsraad; publicatienr.2009\/10.ISBN978\u201090\u20105549\u2010765\u20102."},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410390105"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410360609"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67665-9"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1086\/513793"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.4.1110"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/9.3.330"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113809"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000184748"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.66.6.706"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.09.020"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.003"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-10-199311150-00011"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70215-1"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.3.620"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.11.1467"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1634402"}],"container-title":["Journal of the Peripheral Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1529-8027.2011.00356.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1529-8027.2011.00356.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T01:39:50Z","timestamp":1697333990000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1529-8027.2011.00356.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1111\/j.1529-8027.2011.00356.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1529-8027.2011.00356.x","archive":["Portico"],"relation":{},"ISSN":["1085-9489","1529-8027"],"issn-type":[{"value":"1085-9489","type":"print"},{"value":"1529-8027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}